Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $123.02B | 28.3x | $1,139.80 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.8% Upside | Upgrade to Pro+ | ||
Vertex | NASDAQ | Healthcare | Biotechnology & Medical Research | $120.69B | -246.4x | 2.23 | $467 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11% Upside | Upgrade to Pro+ | |
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | $44.97B | 72.6x | -1.45 | $62.41 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.6% Upside | Upgrade to Pro+ | |
IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | $44B | 30.9x | 0.94 | $241.40 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.5% Upside | Upgrade to Pro+ | |
Alnylam | NASDAQ | Healthcare | Biotechnology & Medical Research | $35.27B | -475.2x | -5.01 | $274.68 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.1% Upside | Upgrade to Pro+ | |
argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $31.88B | -154.2x | -3.07 | $537.40 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6% Upside | Upgrade to Pro+ | |
BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | $26.61B | -47.8x | 0.47 | $112.02 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.3% Upside | Upgrade to Pro+ | |
Moderna | NASDAQ | Healthcare | Biotechnology & Medical Research | $25.25B | -4.3x | 0.01 | $65.71 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.7% Upside | Upgrade to Pro+ | |
ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $24.84B | 34.6x | 0.89 | $299.77 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25% Upside | Upgrade to Pro+ | |
BeiGene ADS | NASDAQ | Healthcare | Biotechnology & Medical Research | $21.11B | -39x | -0.58 | $201.52 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.5% Upside | Upgrade to Pro+ | |
Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $17.02B | -53.9x | -1.73 | $24.53 | 5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.3% Upside | Upgrade to Pro+ | |
Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $16.33B | 20.2x | 1.03 | $25.55 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.7% Upside | Upgrade to Pro+ | |
United Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $15.67B | 15.3x | 0.61 | $351.99 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.5% Upside | Upgrade to Pro+ | |
Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | $14.28B | -25.1x | 0.7 | $115.49 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.9% Upside | Upgrade to Pro+ | |
EXACT Sciences | NASDAQ | Healthcare | Biotechnology & Medical Research | $13B | -73.4x | -1.15 | $70.28 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9% Upside | Upgrade to Pro+ | |
Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | $12.77B | -13.7x | 5.17 | $74.39 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.4% Upside | Upgrade to Pro+ | |
Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | $12.41B | 73.1x | -1.75 | $78.12 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.4% Upside | Upgrade to Pro+ | |
Sarepta | NASDAQ | Healthcare | Biotechnology & Medical Research | $12.10B | 255.4x | 2.4 | $126.60 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Neurocrine | NASDAQ | Healthcare | Biotechnology & Medical Research | $11.95B | 34.6x | 0.41 | $118.16 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42% Upside | Upgrade to Pro+ | |
Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | $11.24B | 33x | 1.17 | $363.88 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.9% Upside | Upgrade to Pro+ | |
Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | $10.54B | 24.3x | -2.06 | $203.99 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.1% Upside | Upgrade to Pro+ | |
Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | $10B | 137.6x | -1.81 | $44.96 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.6% Upside | Upgrade to Pro+ | |
Legend Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.99B | -31.3x | -0.64 | $49.05 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.80B | -15.5x | -0.61 | $153.17 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.4% Upside | Upgrade to Pro+ | |
Viking Therapeutics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.74B | -74.8x | 19.5 | $69.82 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.73B | -5.1x | $53.01 | 5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -10.7% Downside | Upgrade to Pro+ | ||
Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.61B | -12.7x | 1.04 | $45.48 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.5% Upside | Upgrade to Pro+ | |
Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.51B | 22.9x | 0.17 | $26.33 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.3% Upside | Upgrade to Pro+ | |
Halozyme | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.50B | 22.6x | 0.45 | $59.17 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.3% Upside | Upgrade to Pro+ | |
Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.47B | -38.2x | 0.64 | $107.27 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.6% Downside | Upgrade to Pro+ |